Advanced Enzyme Technologies (ADVENZYMES) investor relations material

Executive summary

• Q3 FY26 revenue was INR 1,719 million, up 2% year-over-year but down 7% sequentially; nine-month revenue grew 15% year-over-year to INR 5,424 million.

• Q3 EBITDA declined 11% year-over-year to INR 494 million, while PAT increased 11% to INR 432 million; nine-month PAT rose 20% to INR 1,284 million.

• Human Healthcare contributed 56% of Q3 revenue, with Animal Healthcare and Bioprocessing showing strong growth.

• Board approved up to 26% equity investment in a Group Captive Wind Power Plant SPV and discontinued plans for a solar project.

• Approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.

Financial highlights

• Q3 revenue: INR 1,719 million (+2% YoY, -7% QoQ); nine-month revenue: INR 5,424 million (+15% YoY).

• Q3 EBITDA: INR 494 million (-11% YoY, -18% QoQ); nine-month EBITDA: INR 1,658 million (+11% YoY).

• Q3 PAT: INR 432 million (+11% YoY, -3% QoQ); nine-month PAT: INR 1,284 million (+20% YoY).

• Consolidated net profit for Q3 FY26: Rs 582.91 million, compared to Rs 530.21 million YoY.

• EPS for Q3 FY26 was ₹3.80, up 13% year-over-year.

Outlook and guidance

• Management expects double-digit growth (13–15%) over the next 3–5 years, with continued focus on healthcare and expansion into new enzyme applications.

• Focus areas include expanding animal nutrition, probiotics, bio-catalysis, and baking solutions, with new product launches and global distribution.

• Continued investment in R&D, inorganic expansion, and strategic partnerships are highlighted as growth drivers.

• U.S. market outlook is improving with more inquiries and interest, though tariffs and market uncertainty remain challenges.

• New R&D center in Nashik to focus on strain development, protein engineering, and fermentation, expected to accelerate innovation.